Tag Directory / GENETICS     showing 1–2 of 2   RSS


for: Saturday, August 22, 2026



Supercentenarians have an abundance of cancer-killing immune cells

medicalxpress - The human immune system has specialized cells called CD4 cytotoxic T lymphocytes (CD4 CTLs), which have been shown to kill tumor cells in some cancers. When a person gets sick, these cells multiply in a process called clonal expansion to help fight infect…

AI Summary: Analyses of people over 110 reveal an abundance of highly active cytotoxic immune cells capable of recognizing and eliminating cancerous cells, offering clues to extreme longevity. These hypervigilant immune profiles may explain low cancer rates among the very old and suggest immune‑based strategies that could one day mimic their natural defenses.

10 days / medicalxpress




Ultragenyx Gene Therapy Becomes First FDA-Approved Treatment for Ultra-Rare Disease

Frank Vinluan / medcitynews - Ultragenyx Pharmaceutical’s Genglycos received accelerated FDA approval for glycogen storage disease type Ia, an inherited enzyme deficiency. It’s also the first approved gene therapy for Ultragenyx, which specializes in rare disease treatments. The post …

AI Summary: Ultragenyx received FDA approval for a gene therapy, marking the first approved treatment for that particular ultra‑rare disorder. The decision provides a regulated therapeutic option for patients previously without approved care, highlighting the evolving regulatory willingness to greenlight transformative but small‑population medicines.




Back to Top


GENETICS Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.


StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Biotech, Diabetes, Oncology, Hospital Operations and look for the RSS link.


NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.